"Methods of treating pre-mRNA processing factor 31 (prpf31) gene-mediated conditions"
This is the 1st patent filed in 2023 and it is Retinal Pigmentosa related. It appears that they are bolstering the IP before proceeding to IND and phase 1/2 clinical trials.
The IND could have been delayed by this filing. The timing of this filing is very interesting as it could be based on the wisdom of the high calibre board members. Some of them are getting 2.5M shares p.a. in options as their renumeration. I am sure their contributions are highly valued.
There have been 13 patents filed in 2022 treating various diseases ranging from eye to kidney to CNS as follows:
- 4 patents on Treatment of Monogenic Neurodevelopmental Disorders,
- 3 patents on Treatment of Kidney Disease,
- 1 patent on Methods of Treating Glaucoma,
- 1 Patent on Compositions and Methods for Modulating Autophagy,
- 3 patents on Compositions and Methods for Modulating Inflammation,
- 1 patent on Method Of Treatment for Optic Atrophy,
I wish they would do a press release every time a new patent is being filed, so the shareholders would get a warm and fuzzy feeling that the company is breaking new grounds, It might also mean more new drug(s) ($$$) are to be added to the pipeline in the near future. It would give brokers more substance to recommend this share to their clients and entice those fence sitters to make up their mind to invest buy into PYC. I trust the management do read the HC articles
Right now the share price appears to be artificially kept in the 6 - 7c range. With so much ground being covered in the last 12 months, it is gut wrenching to see the share price got halved from 13.5c. But I am quietly confident that we are very close to the next big step of getting IND approval and the start of human trials. When the massive buy orders start to rush in, the broker(s) who is keeping the low price would no longer be able to do their tricks. It wouldn't be long. We are just weeks away!
(20min delay)